Literature DB >> 30215873

Work environment risks for health care workers with cystic fibrosis.

Scott C Bell1, David Armstrong2, Glenys Harrington3, Luke Jardine4, Rebekah Divakaran5, Bebe Loff6, Peter G Middleton7, Tim McDonald8, Karen Rowland9, Michael Wishart10, Michelle E Wood11, Rhonda L Stuart12.   

Abstract

In Australia and New Zealand, >50% of people with cystic fibrosis (CF) are adults and many of these people are pursuing vocational training and undertaking paid employment. More than 6% of adults with CF are working in health care. There is limited guidance in literature to support health care workers with CF (HCWcf) in training and in employment to support safe practice and to provide protection for themselves and their patients from the acquisition of health care associated infection. A multidisciplinary team of CF and Infectious Disease Clinicians, Infection Prevention and Control Practitioners, HCWcf, academic experts in medical ethics and representatives from universities, appraised the available evidence on the risk posed to and by HCWcf. Specific recommendations were made for HCWcf, CF health care teams, hospitals and universities to support the safe practice and appropriate support for HCWcf.
© 2018 The Authors Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.

Entities:  

Keywords:  cystic fibrosis; health care workers; infection; transmission

Mesh:

Year:  2018        PMID: 30215873     DOI: 10.1111/resp.13404

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  2 in total

1.  Methicillin-resistant Staphylococcus aureus in health-care workers with cystic fibrosis in Sydney.

Authors:  Yang Song; Lucy Rebecca Keatley; Peter Gordon Middleton
Journal:  Respirol Case Rep       Date:  2018-10-29

Review 2.  Infection prevention and chronic disease management in cystic fibrosis and noncystic fibrosis bronchiectasis.

Authors:  Sherstin T Lommatzsch
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.